Anti-HER2 cancer therapy and cardiotoxicity

Area of Science:

• Oncology and Cardiology
• Molecular Biology
• Pharmacology

Background:

• The HER2 receptor is a key target for breast cancer therapy, with drugs like Trastuzumab significantly improving patient survival.
• Trastuzumab, a HER2-targeting monoclonal antibody, is an FDA-approved breast cancer treatment.
• The HER2 receptor plays a vital role in cardiac development and function.

Purpose of the Study:

• To review the potential cardiac impact of anti-HER2 cancer therapies.
• To highlight the link between HER2 inhibition and cardiotoxicity.
• To underscore the need for strategies to mitigate cardiac side effects.

Main Methods:

• Literature review of clinical studies and research on HER2-targeted therapies.
• Analysis of the role of the HER2 receptor in both cancer and cardiac physiology.
• Examination of cardiotoxicity associated with HER2 inhibition.

Main Results:

• Anti-HER2 therapies, including Trastuzumab, Lapatinib, Pertuzumab, and Afatinib, offer significant survival benefits for breast cancer patients.
• A major side effect of HER2-targeted therapy is cardiotoxicity, leading to left ventricular dysfunction and heart failure.
• The HER2 receptor's critical role in cardiac health is now recognized, creating a link between oncology and cardiology.

Conclusions:

• HER2-targeted cancer therapies, while effective, pose a risk of cardiotoxicity.
• Further research is needed to develop therapeutic strategies to prevent or manage cardiac side effects.
• Managing cardiotoxicity is crucial for optimizing treatment outcomes in patients receiving anti-HER2 therapy.